Fig. 3.
The effects of CRF on the proliferation, apoptosis, and cell cycle of human DPCs and human ORSCs. a Dose-dependent effect of CRF on the proliferation of human DPCs. Cells were exposed to CRF at concentrations of 10− 8 M, 10− 7 M, and 10− 6 M for 48 h. b The protective effect of CRF antagonists on the proliferation of human DPCs. The cell number was determined using an EZ-Cytox kit. c The effect of CRF on apoptosis in DPCs. Samples were stained with Annexin V FITC and PI. d Cell cycle analysis of human DPCs at 24, 48, and 72 h after CRF treatment using flow cytometry and e distribution of the cell cycle. f ROS generation after CRF treatment measured using H2DCFDA. CRF antagonists normalized the production of ROS on cultured human DPCs. g Dose-dependent effect of CRF on the proliferation of human ORSCs. Cells were exposed to CRF at concentrations of 10− 8 M, 10− 7 M, and 10− 6 M for 48 h. Ant; antalarmin, A2B; astressin 2-B, C; CRF. p values compared with the normal group by t-test, ##: p < 0.01. p values compared with the CRF treatment group by t-tests, *: p < 0.05, **: p < 0.01